Climb Bio (CLYM) Amortizatization of Intangibles (2021 - 2026)
Climb Bio's (CLYM) quarterly Amortizatization of Intangibles came in at $305000.0 in Q1 2026, down 54.41% YoY from $669000.0 in Q1 2025, and down 40.31% on a QoQ basis from $511000.0 in Q4 2025.
Powered by 
Analysis
Climb Bio (CLYM) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Climb Bio (CLYM) has 6 years of Amortizatization of Intangibles data on file, last reported at $305000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 54.41% year-over-year to $305000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 40.13% YoY) and the FY2025 annual result came in at $2.3 million, up 200.4% from the prior year.
- Amortizatization of Intangibles eased to $305000.0 in Q1 2026, from $511000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $753000.0 in Q3 2023 to a low of -$193000.0 in Q1 2022.
- A 5-year average of $365250.0 and a median of $445500.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles jumped 975.71% — and 2024, when it sank 87.17%.
- Tracing CLYM's Amortizatization of Intangibles over 5 years: stood at $400000.0 in 2022, then retreated by 13.5% to $346000.0 in 2023, then surged by 51.73% to $525000.0 in 2024, then fell by 2.67% to $511000.0 in 2025, then plunged by 40.31% to $305000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $305000.0 (Q1 2026), $511000.0 (Q4 2025), and $523000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Climb Bio | 1.18 Bn | 1.18 Bn | - | 386,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 386,000.00 |
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | 511,000.00 |
| Sep 30, 2025 | 523,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 669,000.00 |
| Dec 31, 2024 | 525,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 346,000.00 |
| Sep 30, 2023 | 753,000.00 |
| Jun 30, 2023 | 741,000.00 |
| Mar 31, 2023 | 491,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Sep 30, 2022 | 70,000.00 |
| Jun 30, 2022 | -100,000.00 |
| Mar 31, 2022 | -193,000.00 |
| Dec 31, 2021 | -287,000.00 |
| Sep 30, 2021 | -83,000.00 |